A006280'un PS Oranı emsallerine kıyasla nasıldır?

A006280 is good value based on its Price-To-Sales Ratio (1.1x) compared to the peer average (31.4x).

A006280'nin PS Oranı, KR Biotechs Sektöründeki diğer şirketlerle karşılaştırıldığında nasıldır?

A006280 is good value based on its Price-To-Sales Ratio (1.1x) compared to the KR Biotechs industry average (9.8x).

A006280'nin PS Oranı, Adil PS Oranına kıyasla nedir? Bu, şirketin tahmini kazanç büyümesini, kar marjlarını ve diğer risk faktörlerini dikkate alan beklenen PS Oranıdır.

A006280 is good value based on its Price-To-Sales Ratio (1.1x) compared to the estimated Fair Price-To-Sales Ratio (2.5x).

Gelecekteki nakit akışlarına bakıldığında A006280 'un Adil Fiyatı nedir? Bu tahmin için İndirgenmiş Nakit Akışı modelini kullanıyoruz.

A006280 (₩162500) is trading above our estimate of [[fair value]] (₩38285.61)

Analistin 12 aylık tahmini nedir ve konsensüs fiyat hedefine istatistiksel olarak güveniyor muyuz?

Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

GC Biopharma (KOSE:A006280) - Hisse Senedi Fiyatı, Haberler ve Analizler

A006280 Stoklara Genel Bakış

Bir biyofarmasötik şirketi olan GC Biopharma Corp. Güney Kore'de ve uluslararası alanda farmasötik ilaçlar geliştirmekte ve satmaktadır.

Şirket hakkında

A006280 temel anali̇z
Kar Tanesi Skoru
Değerleme	4/6
Gelecekteki Büyüme	3/6
Geçmiş Performans	0/6
Finansal Sağlık	2/6
Temettüler	0/6

Ödüller

Earnings are forecast to grow 102.28% per year

Trading at good value compared to peers and industry

Analysts in good agreement that stock price will rise by 23.1%

Risk Analizi

Interest payments are not well covered by earnings

GC Biopharma Corp. Rakipler

ABL Bio

KOSDAQ:A298380

₩1.9t

NatureCellLtd

KOSDAQ:A007390

₩1.4t

Hugel

KOSDAQ:A145020

₩3.2t

PharmaResearch

KOSDAQ:A214450

₩2.4t

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti GC Biopharma
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	₩162,500.00
52 Haftanın En Yüksek Seviyesi	₩181,800.00
52 Haftanın En Düşük Seviyesi	₩100,000.00
Beta	1.03
11 Aylık Değişim	7.69%
3 Aylık Değişim	15.33%
1 Yıllık Değişim	57.92%
33 Yıllık Değişim	-32.85%
5 Yıllık Değişim	32.65%
Halka arzdan bu yana değişim	-45.40%

Son Haberler & Güncellemeler

Is GC Biopharma (KRX:006280) A Risky Investment?

Oct 17

Recent updates

GC Biopharma Corp.'s (KRX:006280) Business And Shares Still Trailing The Industry

Mar 08

We Think Green Cross (KRX:006280) Can Stay On Top Of Its Debt

May 02

Are Green Cross Corporation's (KRX:006280) Mixed Financials Driving The Negative Sentiment?

Mar 10

Shareholders Are Thrilled That The Green Cross (KRX:006280) Share Price Increased 268%

Feb 18

Green Cross (KRX:006280) Has A Somewhat Strained Balance Sheet

Jan 31

Calculating The Intrinsic Value Of Green Cross Corporation (KRX:006280)

Jan 14

What You Need To Know About Green Cross Corporation's (KRX:006280) Investor Composition

Dec 27

Green Cross Corporation's (KRX:006280) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Dec 09

Does Green Cross's (KRX:006280) Statutory Profit Adequately Reflect Its Underlying Profit?

Nov 21

Hissedar Getirileri

	A006280	KR Biotechs	KR Pazar
7D	-0.3%	1.7%	-0.5%
1Y	57.9%	42.1%	1.0%

Getiri vs. Endüstri: A006280 exceeded the KR Biotechs industry which returned 41.8% over the past year.

Getiri vs Piyasa: A006280 exceeded the KR Market which returned 4.8% over the past year.

Fiyat Oynaklığı

Is A006280's price volatile compared to industry and market?
A006280 volatility
A006280 Average Weekly Movement	8.5%
Biotechs Industry Average Movement	9.5%
Market Average Movement	6.7%
10% most volatile stocks in KR Market	12.2%
10% least volatile stocks in KR Market	3.5%

İstikrarlı Hisse Senedi Fiyatı: A006280 has not had significant price volatility in the past 3 months compared to the KR market.

Zaman İçindeki Volatilite: A006280's weekly volatility (9%) has been stable over the past year.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1967	2,016	Il-Sup Huh	www.globalgreencross.com

Bir biyofarmasötik şirketi olan GC Biopharma Corp. Güney Kore'de ve uluslararası alanda farmasötik ilaçlar geliştirmekte ve satmaktadır. Analjezik ve anti-enflamatuar etki için Acustop Cataplasma; anti-enflamatuar için Kenhancer plaster; ve anti-enflamatuar ve ağrı kesici tedavi için Zenol Cool Type ve Zenol Mild Hot Type ilaçları gibi reçetesiz satılan ilaçlar sunmaktadır. Şirket ayrıca akut kanamada hipoalbüminemi ve şokun yanı sıra düşük albümin sentezi için Albumin-GCC enjeksiyonu (inj.); Kalıtsal antitrombin-III eksikliği için Antitrombin-III (AT-III) enjeksiyonu; Hemofili B için Facnyne inj.

GC Biopharma Corp. Temel Bilgiler Özeti

GC Biopharma'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
A006280 temel i̇stati̇sti̇kler
Piyasa değeri	₩1.85t
Kazançlar(TTM)	-₩38.20b
Gelir(TTM)	₩1.62t

1.1x

P/S Oranı

-48.6x

F/K Oranı

A006280 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
A006280 gelir tablosu (TTM)
Gelir	₩1.62t
Gelir Maliyeti	₩1.16t
Brüt Kâr	₩457.90b
Diğer Giderler	₩496.09b
Kazançlar	-₩38.20b

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-3.35k
Brüt Marj	28.29%
Net Kâr Marjı	-2.36%
Borç/Özkaynak Oranı	52.3%

A006280 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

0.9%

Mevcut Temettü Verimi

-45%

Ödeme Oranı

A006280 Stoklara Genel Bakış

Ödüller

Risk Analizi

GC Biopharma Corp. Rakipler

KOSDAQ:A298380

₩1.9t

KOSDAQ:A007390

₩1.4t

KOSDAQ:A145020

₩3.2t

KOSDAQ:A214450

₩2.4t

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Price target increased by 10% to ₩195,000

Now 21% overvalued after recent price rise

Is GC Biopharma (KRX:006280) A Risky Investment?

Price target increased by 11% to ₩188,333

GC Biopharma and Hanmi Pharmaceutical Receives IND Clearance for Phase 1/2 Clinical Trial from the U.S. FDA

Price target increased by 7.7% to ₩162,000

Recent updates

Price target increased by 10% to ₩195,000

Now 21% overvalued after recent price rise

Is GC Biopharma (KRX:006280) A Risky Investment?

Price target increased by 11% to ₩188,333

GC Biopharma and Hanmi Pharmaceutical Receives IND Clearance for Phase 1/2 Clinical Trial from the U.S. FDA

Price target increased by 7.7% to ₩162,000

There's No Escaping GC Biopharma Corp.'s (KRX:006280) Muted Revenues

Now 21% overvalued after recent price rise

A Look At The Fair Value Of GC Biopharma Corp. (KRX:006280)

New major risk - Financial position

Is GC Biopharma (KRX:006280) A Risky Investment?

Gc Biopharma and Novel Pharma Announce Sanfilippo Syndrome Treatment Obtains FDA IND Approval

GC Biopharma Corp.'s (KRX:006280) Business And Shares Still Trailing The Industry

Upcoming dividend of ₩1,750 per share at 1.4% yield

GC Biopharma Corp. Announces US FDA Approval for ALYGLO (Immune Globulin Intravenous, Human-Stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI)

Consensus EPS estimates fall from profit to ₩269 loss

GC Biopharma Applies for MFDS Approval

Consensus EPS estimates fall from profit to ₩1,046 loss

Consensus EPS estimates fall by 31%

Now 21% undervalued after recent price drop

Consensus EPS estimates increase by 18%, revenue downgraded

GC Biopharma's "GC FLU" Obtains Vaccine Approval in Egypt

Consensus EPS estimates fall by 38%

Consensus EPS estimates increase by 11%

GC Biopharma Receives a Business License for the Construction of a Plasma Fractionation Plant and Technology Transfer in Indonesia

Full year 2022 earnings: EPS exceeds analyst expectations

Price target decreased to ₩176,750

Upcoming dividend of ₩2,000 per share

Price target decreased to ₩191,222

Less than half of directors are independent

Now 21% undervalued after recent price drop

Price target decreased to ₩208,875

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analyst expectations

Less than half of directors are independent

Price target decreased to ₩254,400

GC Pharma Receives Complete Response Letter From the U.S. FDA For 'ALYGLO'

Investor sentiment improved over the past week

Price target decreased to ₩310,167

Consensus forecasts updated

Upcoming dividend of ₩1,500 per share

Price target decreased to ₩418,333

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

GC Pharma Announces Publication of Results From Phase III Clinical Trial of ‘GC5107’ Immune Globulin in Frontiers in Immunology

Price target increased to ₩434,000

Price target increased to ₩383,000

First quarter 2021 earnings released: EPS ₩1,293 (vs ₩368 loss in 1Q 2020)

US FDA Accepts GC Pharma’s Biologics License Application for Immune Globulin 'GC5107'

We Think Green Cross (KRX:006280) Can Stay On Top Of Its Debt

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS ₩7,087 (vs ₩118 in FY 2019)

Are Green Cross Corporation's (KRX:006280) Mixed Financials Driving The Negative Sentiment?

New 90-day low: ₩333,500

GC Pharma Finalises Agreement with Moderna and the Government of the Republic of Korea for Covid-19 Vaccines Distribution

GC Pharma Submits Biologics License Application to US FDA for Immune Globulin 'GC5107'

Shareholders Are Thrilled That The Green Cross (KRX:006280) Share Price Increased 268%

Green Cross Corporation, Annual General Meeting, Mar 25, 2021

Green Cross (KRX:006280) Has A Somewhat Strained Balance Sheet